EliteTrading

$CEVA 52 week high range with MAJOR catalysts ahead. 📈📈📈🔥 We were early @TerpsTrader1 $AAPL ITM on our swing. Big ITM on those 300's 🤑🤙 $HPE Big ITM on our $33 calls. CEVA is next!

🚀 Top 10 Gainers Snapshot 🔹 $QTEX +183.2% 🔹 $RYOJ +150.2% 🔹 $PCLA +131.6% 🔹 $AKTX +116.5% 🔹 $BIYA +100.8% 🔹 $LFS +87.3% 🔹 $MEHA +51.9% 🔹 $VCIG +49.9% 🔹 $KIDZ +46.4% 🔹 $GOVX +42.9%

🚨 $ENHA HISTORY IN THE MAKING THIS WEEKEND 📅 The Enhanced Games are coming to Las Vegas on Sunday, May 24, 2026 at Resorts World Las Vegas. 🔹 50+ elite athletes 🔹 Track, swimming & weightlifting 🔹 Global livestream event 🔹 A new era of elite competition ENHA is positioning itself at the center of one of the most talked about sports events of 2026. 👀 #ENHA #EnhancedGames #stocks #sports #LasVegas #investing #stockmarket #smallcaps #trading

@TheShortSqueezy Tapping into a growing 200B $ market.

🚨 $CUE Entering a New Growth Phase With Major 2026 Catalysts Cue Biopharma is developing targeted immune therapies designed to selectively activate the body’s immune system for cancer and autoimmune diseases using its proprietary Immuno-STAT platform. Cue Biopharma continues stacking catalysts in 2026: 🔹 Presenting at the Jefferies Global Healthcare Conference on June 3rd, giving CUE major exposure to institutional healthcare investors. 🔹 Expanded pipeline with Ascendant-221, a clinical stage anti-IgE antibody targeting allergic diseases and expanding CUE into large immunology markets. 🔹 Company also secured a $30M private placement to strengthen the balance sheet and support pipeline expansion. 🔹 Received a $7.5M milestone payment from Boehringer Ingelheim, further validating the company’s immune-modulation platform. With oncology and allergy/immunology markets representing multi billion dollar opportunities globally, CUE is positioning itself in some of the largest and fastest-growing areas in biotech. Communicated Disclaimer: stockresearchtoday.com/cue/ Sector peers: $MRNA $BNTX $ADAP $NKTX $IMTX $SANA $CRSP $BEAM $XCUR $HOOK $INMB $ABCL $RVPH $XBI

@tr6ding Solid catalysts ahead and a 200B $ market. 🔥

$CUE just stacked multiple major catalysts heading into H2 2026 👀 • Presenting at Jefferies Global Healthcare Conference June 3 • $345M potential Boehringer Ingelheim partnership + royalties • Locked in $7.5M milestone payment in April • Phase 2 anti-IgE allergy data expected 2H26 • Q1 revenue surged to $5.7M vs $0.4M YoY • Net loss narrowed significantly • New CEO Shao-Lee Lin (founder of ACELYRIN — $2B+ IPO) • Fresh $27.6M raise to power the pipeline Positioning as a next-gen immunology name focused on selective immune modulation and potential functional cures in autoimmune + allergic diseases. Strong leadership upgrade, big pharma validation, clinical momentum, and improving financials. These biotech setups can rip when the catalysts hit. Positioning early..​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​ Communicated Disclaimer - stockresearchtoday.com/cue/

@JulesTradesInc 200B $ + market is no joke. They are tapping into something big.

🚨 $CUE A name WELL POSITIONED for major growth in a 200 BILLION 💲 MARKET.  Cue Biopharma is advancing its Immuno-STAT platform across cancer, autoimmune, and allergy diseases, targeting a global cancer immunotherapy market projected to reach $$200B+ this decade. 📅  2026 CATALYSTS: ▪️ Presenting at the Jefferies Global Healthcare Conference on June 3rd. ▪️ Expanded pipeline with Ascendant-221 targeting allergic diseases. ▪️ Secured $30M private placement to support growth. ▪️ Received $7.5M milestone payment from Boehringer Ingelheim. CUE has exposure in some of biotech’s largest global markets, and they are positioning for a potentially major expansion phase into 2027. Communicated-Disclaimer:  stockresearchtoday.com/cue/

@TradershubNinja 200B $ + market, and growing!

$CUE PRECISION IMMUNE MODULATION STORY HEATING UP Cue Biopharma is developing engineered biologics designed to selectively target disease-specific T cells across autoimmune, inflammatory & oncology indications. ✅ $30M private placement ✅ New CEO with major biotech leadership experience ✅ Boehringer deal worth up to $345M + royalties ✅ $7.5M milestone earned in April 2026 ✅ Q1 collaboration revenue surged to $5.7M vs $0.4M ✅ Net loss narrowed to $5.2M from $12.3M ✅ Phase 2 allergic disease data expected 2H 2026 If Big Pharma validation + fresh capital + pipeline catalysts are lining up… Is CUE being overlooked before the next major biotech rerating? Communicated - Disclaimer: stockresearchtoday.com/cue/

🚨 $CUE Gaining Attention With Big 2026 Catalysts. The Cancer immunotherapy market is a $150B–$200B+ projected global market this decade. CUE continues advancing its Immuno-STAT platform across cancer and autoimmune diseases. ➡️ Presenting at the Jefferies Global Healthcare Conference on June 3rd ➡️ Expanded pipeline with Ascendant-221 targeting allergic diseases ➡️ Secured $30M private placement to fuel growth ➡️ Received $7.5M milestone payment from Boehringer Ingelheim With exposure to major oncology and immunology markets, CUE is entering a new phase of growth in biotech. A name to keep on your radar into 2027! Communicated-Disclaimer- stockresearchtoday.com/cue/

$AAPL 300c deep ITM now waiting on our 310c 🤑💲 $NVDA Paid us handsomely lately. $CEVA under the radar name to watch! Big catalysts. 👇👇

@hobohobbitt Yeah that baby runs hard when it does! I missed it too.

@EliteGainzTrade Can’t believe I missed $AKAN again! Wtf 😭. Are you accepting new ppl on telegram? What’s the link?

💲💲 Top Gainers 💲💲 $AKAN +87.7% $ATPC +71.8% $CODX +63.4% $NIVF +58.3% $PCLA +56.4% 🚨 SMALL CAPS HEATING UP 🚨 Biotech + low float momentum names are leading today’s action with huge volume, PR catalysts, and breakout setups. Watch: $AKAN $ATPC $CODX $NIVF $PCLA 📈 Also moving: $NCPL $LIMN $AKTX $PIII $EDHL $WHLR $INFQ $SBFM $NEOV $GOVX

@belfort0609 @buyerofponzi @IBKR I'm hearing this is an increasing problem. You will be better off elsewhere .. IBKR went from a top tier broker to a bottom tier real fast as far as I'm concerned.

The level of incompetence at @IBKR is impressive. 8 days I've had my account locked with a position open costing me thousands of dollars. Everyday I'm on the phone with them for hours being passed to the next department @IBKR you guys suck so bad

@buyerofponzi @IBKR Terrible service, perhaps the worst. I've had countless glitches and had my account locked before too.

$OKLO - $764K Call buyer. Next week expiration

@IBKR Terrible broker with so many new restrictions and glitches.

IBKR launched access to the 3 major U.S. prediction markets—Kalshi, CME & ForecastEx—all on one powerful platform. Open an account today. ibtweet.com/twitter861op Futures, event & forecast contracts are not suitable for all investors. IB LLC, Member SIPC. Ibkr.com/info"

@IBKR Terrible broker with so many new restrictions and glitches.

Watch IBKR Founder Thomas Petterfy discuss the future of prediction markets on CNBC: cnbc.com/video/2026/05/… Futures, event & forecast contracts are not suitable for all investors. IB LLC, Member NFA, SIPC. ibkr.com/info

🚨 TRADING LESSON #1: SIMPLE STRATEGY THAT ACTUALLY WORKS Most traders lose because they overcomplicate everything. Often with too many indicators! 🔹 Trade WITH the trend 🔹 Buy near support 🔹 Respect resistance 🔹 Always protect capital with a stop loss 🔹 Let risk management do the heavy lifting The goal isn’t to predict every move… it’s to react smart and stay disciplined. 📈 Patience + consistency > chasing hype. 🔥 Like & Follow for more Elite Trading lessons, setups, chart patterns, and market education. #Trading #Stocks #DayTrading #SwingTrading #StockMarket #Investing #Trader #TradingTips #TechnicalAnalysis #RiskManagement #StockTrader #Finance #Money #Wealth #BullMarket #TradingEducation #OptionsTrading #SPY #QQQ #NVDA #FYP #Viral

📝 Stop Loss Lesson For Traders 📝 Most traders lose because of bad risk management .. not bad entries. 🎯 Smart stop losses protect your capital, avoid emotional trading, and keep you alive for the next setup. 🔹 Don’t place stops at obvious round numbers 🔹 Give trades room to breathe with volatility buffers 🔹 Let chart structure decide your stop 🔹 Size your position based on risk and not emotion Bad stops get hunted. Smart stops keep you in the game. 📈 $SPX $SPY $QQQ $SLXN $JUNS $GCL $MWC $PHGE $RKDA $GDC $IMVT $VIDA $PETZ $HAO $QTEX $AMPG $TDIC $EGHT

BREAKING: 🇮🇷 🇺🇸 This is a major blow to Donald Trump. The US Senate voted 50-47 to advance a resolution to limit military action against Iran unless approved by Congress.